SEARCH

SEARCH BY CITATION

References

  • 1
    Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone. 2002; 31:17.
  • 2
    Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010; 2:195214.
  • 3
    Yamagishi S-I. Role of advanced glycation end products (AGE) in osteoporosis in diabetes. Curr Drug Targets. 2011; 11:2096102.
  • 4
    Reddy S, Bichler J, Wells Knecht KJ, Thorpe SR, Baynes JW. N-epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995; 34:108728.
  • 5
    Vashisth D. Advanced glycation end products and bone fracture. IBMS Bonekey. 2009; 6:26878.
  • 6
    Gineyts E, Munoz F, Bertholon C, Sornay-Rendu E, Chapurlat R. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int. 2010; 21:24350.
  • 7
    Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008; 26:93100.
  • 8
    Tanaka S, Kuroda T, Saito M, Shiraki M. Urinary pentosidine improves risk classification using fracture risk assessment. J Bone Miner Res. 2011; 26:277884.
  • 9
    Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93:10139.
  • 10
    Schwartz AV, Garnero P, Hillier TA, et al.; Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94:23806.
  • 11
    Hein G, Wiegand R, Lohmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysineare elevated in serum of patients with osteoporosis. Rheumatology (Oxford). 2003; 42:12426.
  • 12
    Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:26376.
  • 13
    Cushman M, Cornell ES, Howard PR, Boville EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995; 41:26470.
  • 14
    Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and inflammation as precursors of frailty: The Cardiovascular Health Study. Arch Intern Med. 2007; 167:63541.
  • 15
    Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of Nϵ-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004; 47:13769.
  • 16
    Zhang X, Frischmann M, Kientsch-Engel R, et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med. 2005; 43:50311.
  • 17
    Wilcox R. Trimming and Winsorization. Encyclopedia of biostatistics. Hoboken, HJ: Wiley Online Library; 2005.
  • 18
    R Foundation for Statistical Computing. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing [updated 2013 Sep 25; cited 2013 Dec 14]. Available from: http://www.R-project.org.
  • 19
    Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006; 39:10739.
  • 20
    Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006; 17:98695.
  • 21
    Karim L, Tang SY, Sroga GE, Vashishth D. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013; 24:24417.
  • 22
    Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol. 2008; 600:1407.
  • 23
    Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007; 25:57783.
  • 24
    Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004; 64:45970.